UNS, page-36

yes, it's gone from a coy that was virtually insolvent, to a coy that should be investment grade, growth potential, certain sales revenue from Amgen, and flush with funds.
it gets immediate US$15m, then gets funds from pre-sales to Amgen, then gets big equity injection, then gets platform to sell its product to other parties. - plus the benefit of association with Amgen.

so how can the mkt only value this coy-changing event at an extra 8c? ie from 12c ->20c?

its a different coy now